↓ Skip to main content

Dove Medical Press

Eldecalcitol for the treatment of osteoporosis

Overview of attention for article published in Clinical Interventions in Aging, September 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
3 X users
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
39 Mendeley
citeulike
1 CiteULike
Title
Eldecalcitol for the treatment of osteoporosis
Published in
Clinical Interventions in Aging, September 2013
DOI 10.2147/cia.s49825
Pubmed ID
Authors

Yuko Noguchi, Hisaya Kawate, Masatoshi Nomura, Ryoichi Takayanagi

Abstract

Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (>11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 18%
Student > Bachelor 5 13%
Researcher 5 13%
Other 4 10%
Student > Doctoral Student 3 8%
Other 7 18%
Unknown 8 21%
Readers by discipline Count As %
Medicine and Dentistry 13 33%
Nursing and Health Professions 4 10%
Agricultural and Biological Sciences 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Immunology and Microbiology 2 5%
Other 6 15%
Unknown 9 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2022.
All research outputs
#7,205,554
of 25,374,917 outputs
Outputs from Clinical Interventions in Aging
#684
of 1,968 outputs
Outputs of similar age
#58,911
of 212,478 outputs
Outputs of similar age from Clinical Interventions in Aging
#18
of 51 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,968 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,478 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.